Our clinic remains open for participant study visits during all alert levels.  ||  Our US Toll Free #: 1844 264 6291

SABER™ Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control...

SABER™- Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control demonstrates dose-response, safety and no impact on surgical wound healing following inguinal herniorrhaphy.

SABER-Bupivacaine is an extended release formulation of bupivacaine in a resorbable matrix which provides delivery of bupivacaine at the site of administration over a period of 3 days. The formulation consists of three components: common local anesthetic bupivacaine (12%), organic matrix sucrose acetate isobutyrate, and a diluent, benzyl alcohol. Clinical benefits and safety of continuous infusions of bupivacaine into the surgical wound via elastomeric pumps was demonstrated following a variety of surgical procedures (Liu, 2006), including inguinal hernia repair (Lau, 2003; Sanchez, 2004). SABER-Bupivacaine formulation, a translucent thick solution, is designed to provide continuous delivery of bupivacaine once placed in the surgical wound at the same rate of 10-20 mg/h as delivered by elastomeric pumps through indwelling catheters. Multiple trials are ongoing to investigate safety and efficacy of SABER-Bupivacaine in various surgical procedures.

Hadj A, Nicholson D, Moodie J, Turner R, Watts R, Abrouk N, Langecker P, Lissin D.

Poster presentation American Society of Anaesthesiologists, October 15 2014.

Read publication...